tert-butyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate | 926659-00-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate
• 英文别名: 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylic acid tert-butyl ester；3,9-Diazabicyclo[3.3.1]nonane-3-carboxylic acid, 7-oxo-9-(phenylmethyl)-, 1, 1-dimethylethyl ester
• CAS: 926659-00-9
• 化学式: C₁₉H₂₆N₂O₃
• 分子量: 330.427
• InChiKey: MNUXBVXVOYGWFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate 在 palladium dihydroxide 氢气 作用下， 以 甲醇 为溶剂， 反应 48.0h， 以100%的产率得到7-氧代-3,9-二氮杂双环[3.3.1]壬烷-3-羧酸叔丁酯
  参考文献：
  名称：

  WO2007/22502

  摘要：

  公开号：
• 作为产物：
  描述：

  N-Boc-3-吡咯啉 在 sodium periodate 、 四氧化锇 、 sodium acetate 、 N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 35.5h， 生成 tert-butyl 9-benzyl-7-oxo-3,9-diazabicyclo[3.3.1]nonane-3-carboxylate
  参考文献：
  名称：

  COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS

  摘要：

  The present invention relates to compounds of Formulas I to V and Ib to Vb, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5'-adenosine monophosphate (cAMP).

  公开号：

  WO2024038129A1

文献信息

• Bridged N-Cyclic Sulfonamido Inhibitors of Gamma Secretase
  申请人：Bowers Simeon

  公开号：US20080090817A1

  公开（公告）日：2008-04-17

  The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R 1 and R 2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

  本发明提供了N-环状磺酰胺化合物和公式I的盐：其中A如规范所述，而R1和R2组合形成[3.3.1]或[3.2.1]环系统，其中氮连接到两个桥头碳，并且[3.3.1]或[3.2.1]环系统可以与杂环芳基或杂环烷基环融合。公式I的化合物可用于治疗或预防认知障碍，如阿尔茨海默病。本发明还包括包含公式I化合物的制药组合物，治疗认知障碍的方法，如阿尔茨海默病，以及制备公式I化合物的中间体。
• Bridged N-cyclic sulfonamido inhibitors of gamma secretase
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US07345056B2

  公开（公告）日：2008-03-18

  The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and R1 and R2 combine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.

  本发明提供了公式I的N-环磺酰胺化合物和盐，其中A如规范所述，R1和R2结合形成[3.3.1]或[3.2.1]环系统，其中氮原子连接到两个桥头碳原子，并且[3.3.1]或[3.2.1]环系统可以与杂环芳基或杂环烷基环融合。公式I的化合物可用于治疗或预防认知障碍，如阿尔茨海默病。本发明还包括包含公式I化合物的制药组合物，治疗认知障碍的方法，如阿尔茨海默病，以及制备公式I化合物的中间体。
• N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase
  作者：Simeon Bowers、Gary D. Probst、Anh P. Truong、Roy K. Hom、Andrei W. Konradi、Hing L. Sham、Albert W. Garofalo、Karina Wong、Erich Goldbach、Kevin P. Quinn、John-Michael Sauer、William Wallace、Lan Nguyen、Susanna S. Hemphill、Michael P. Bova、Guriqbal S. Basi

  DOI：10.1016/j.bmcl.2009.10.060

  日期：2009.12

  The structural modification of a series of [3.3.1] bicyclic sulfonamide based gamma-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile. (C) 2009 Elsevier Ltd. All rights reserved.
• BRIDGED N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE
  申请人：Elan Pharmaceuticals Inc.

  公开号：EP1916985A2

  公开（公告）日：2008-05-07
• US7345056B2
  申请人：——

  公开号：US7345056B2

  公开（公告）日：2008-03-18